Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: michel petit who wrote (337)	7/16/1999 11:49:00 AM
From: sim1	Read Replies (1) \| Respond to of 422

Acquisition target? Wouldn't surprise me. Abbott Labs has some related businesses. I'm sure there are others. abbott.com abbott.com

To: michel petit who wrote (337)	7/31/1999 11:22:00 AM
From: Thomas Kirwin	Respond to of 422

Register & Akers Fast Facts #1 - #5 R&A Fast Fact #1 - Market Share "Immucor now holds 54% share. The company has also enhanced its overseas presence with a variety of deals in Europe and Japan, increasing its worldwide market share to 23%. This clearing of the competitive landscape should allow firming in industry pricing, under considerable pressure for the last few years, while enabling Immucor to obtain premium pricing on reagent packages sold with its instrument line." R&A Fast Fact #2 - Revenue Growth "We are looking for revenues to advance 52% to over $90 million in FY2000, with $12 million in incremental sales from full year contributions of acquisitions made last year, instrument sales more than doubling, and the sale of more and higher-priced reagents." R&A Fast Fact #3 - EPS Growth "Higher operating margins should allow EPS to grow by 67% to $0.70 per share. Continuing margin expansion on higher instrument and reagent sales should propel EPS to $1.10 or more in FY2001. Moreover, we believe these estimates to be conservative, especially if the company has success in landing large national accounts' R&A Fast Fact #4 - Market Capitalization "Immucor's market capitalization has now passed the magic $100 million mark, making it eligible for consideration by fund managers with minimum size requirements. We expect the stock to attract an increasing investor following, and receive a higher valuation.' R&A Fast Fact #5 - Target Price "We strongly recommend purchase of BLUD shares in aggressive accounts with a 12 to 18 month target of $28." Best O'Luck, Tom

To: michel petit who wrote (337)	10/2/1999 1:41:00 PM
From: Thomas Kirwin	Respond to of 422

Two more reasons to BUY & OWN Immucor! Immucor places #1 & #3 in market share! I have a slew friends that say you can't go wrong by investing in a company that is #1 or #2 in market share. Immucor commands the #1 spot in North America and stands at #3 in the WORLD. Immucor will be numero uno in the universe soon enough. Our day is coming! Best O'Luck, Tom